Phoenix Pharmalabs is a pre-clinical pharmaceutical company based in San Francisco, CA, dedicated to providing potent and safe pain therapies without the risk of addiction and serious side effects. Their lead candidate, PPL-138, offers robust preclinical validation of potent pain relief with 100X potency of morphine and a low risk of abuse and addiction. Additionally, their second drug candidate, PPL-103, shows promising potential for the treatment of addiction and pain, with reduced opioid side effects.
With more than $23 million raised to date from grants and investments, Phoenix Pharmalabs aims to capture a significant portion of the $30 billion opioid therapeutics market. Their portfolio of drugs under development has unique opioid receptor characteristics that address the unmet medical need for comprehensive solutions to abuse, addiction, and mortality associated with opiates. The company actively seeks business and investment relationships to advance their drug candidates through pre-clinical and clinical trials.
Generated from the website